Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions
WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting being held March 10-14 in San Diego. During the meeting, the Company's booth will prominently feature its comprehensive hip portfolio, anchored by the new Z1™ Triple-Taper Femoral Hip System, along with the latest technologies for knee and upper extremity reconstruction and key components from its robotic solutions. In addition, Zimmer Biomet is debuting ZBX™, its new Ambulatory Surgery Center (ASC) offering to surgeons and institutions looking to expand their orthopedic footprint.
"I am thrilled to showcase the collective strength and broad range of our musculoskeletal portfolio, including the introduction of several recently cleared technologies, at this year's annual AAOS meeting," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet. "We are in the midst of one of the largest innovation cycles in our company's history. Our broad hip reconstruction portfolio combined with our comprehensive knee portfolio with constructs designed to safeguard against cement and metal sensitivities, our bone-preserving stemless shoulder and now an enhanced suite of ASC solutions, squarely position us at the forefront of delivering customer-centric innovations to improve efficiency and overall patient outcomes."
The highlights at the Zimmer Biomet booth (#3129) include:
Hip Reconstruction Technologies
Knee Reconstruction Technologies
Upper Extremities Technology
ASC Solutions
For more information about Zimmer Biomet events at AAOS 2025, visit www.zimmerbiomet.com/academy2025.
Important Safety Information for Oxford Cementless Partial Knee:
The Oxford® Cementless Partial Knee System is indicated for use in unilateral knee procedures with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. It is intended to be implanted without the application of bone cement for patients whose clinical condition would benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee Is not indicated for use in the lateral compartment or for patients with ligament deficiency, or for use in simultaneous bilateral surgery or planned staged bilateral procedures. Potential risks include, but are not limited to, loosening, dislocation, fracture, wear and infection, any of which can require additional surgery. For a full list of product indications, contraindications and warnings, please see the associated product Instructions For Use (IFU).
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the Company's expectations, plans, intentions, strategies, prospects, business plans, product and service offerings, new product launches, potential clinical successes, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
References:
Laboratory and animal studies are not necessarily indicative of clinical performance.
HipInsight™ System is a trademark of Surgical Planning Associates, Inc.
Microsoft and HoloLens 2 are trademarks of the Microsoft Corporation.
Persona IQ: The objective kinematic data generated by the Canary Canturio® Tibial Extension with CHIRP® System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.
345 E. Main St.
Warsaw, IN 46580
www.zimmerbiomet.com
| Media | Investors |
| Heather Zoumas-Lubeski | David DeMartino |
| 445-248-0577 | 646-531-6115 |
| heather.zoumaslubeski@zimmerbiomet.com | david.demartino@zimmerbiomet.com |
| Kirsten Fallon | Zach Weiner |
| 781-779-5561 | 908-591-6955 |
| kirsten.fallon@zimmerbiomet.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-highlights-diverse-portfolio-of-orthopedic--musculoskeletal-innovations-at-aaos-2025-annual-meeting-302396091.html
SOURCE Zimmer Biomet Holdings, Inc.

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.